Microbiome Vaginae After Use of Oral Probiotics in Pregnancy.
Development of Microbiome Vaginae After Use of Oral Probiotics in First the Trimester of Pregnancy. A Prospective Pilot Study
1 other identifier
interventional
44
1 country
1
Brief Summary
Change of Vaginal microbiome in first trimester pregnant women after oral intake of Probiotic preparation with 4 lactobacilli strains
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Aug 2022
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
February 23, 2021
CompletedFirst Posted
Study publicly available on registry
March 3, 2021
CompletedStudy Start
First participant enrolled
August 15, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 1, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
May 1, 2023
CompletedNovember 15, 2022
November 1, 2022
8 months
February 23, 2021
November 14, 2022
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
CST
change of vaginal microbiome after probiotic intake
14 Days
Secondary Outcomes (1)
Lactobacilli Change
14 Days
Study Arms (1)
Probiotic group
EXPERIMENTALpilot study with one interventional group
Interventions
containing four Lactobacillus strains (Lactobacillus crispatus -Lbv88, Lactobacillus rhamnosus -Lbv96, Lactobacillus jensenii -Lbv116, and Lactobacillus gasseri -Lbv150)
Eligibility Criteria
You may qualify if:
- Pregnant women aged between 18 and 45
- infection screening during a prenatal consultation between 10+0 (10 weeks plus 0 days) and 16+0 (16 weeks plus 0 days) gestational weeks
- Singleton pregnancy
You may not qualify if:
- Vaginal infections such as Bacterial vaginosis, candida vaginitis, trichomoniasis, mycoplasma, gonococcal infection
- Antibiotic therapy in the last 4 weeks
- Probiotic therapy in the last 4 weeks
- Operation on gastrointestinal tract
- Diarrhoea, obstipation
- Vaginal bleeding
- Patients with hormone disorders of any kind
- Other chronic diseases (Diabetes, Autoimmune diseases etc.)
- HIV
- Gestational diabetes
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Department of Obstetrics and Gynecology, Medical University of Vienna
Vienna, 1090, Austria
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Ljubomir Petricevic, Prof Dr
Medical University Vienna
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- principal investigator
Study Record Dates
First Submitted
February 23, 2021
First Posted
March 3, 2021
Study Start
August 15, 2022
Primary Completion
April 1, 2023
Study Completion
May 1, 2023
Last Updated
November 15, 2022
Record last verified: 2022-11
Data Sharing
- IPD Sharing
- Will not share